2025 United States Amyotrophic Lateral Sclerosis (Als) Treatment Revenue Opportunities Report
Description
The 2025 United States Amyotrophic Lateral Sclerosis (Als) Treatment Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Amyotrophic Lateral Sclerosis (ALS) Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in ALS treatment in the United States are Biogen, Mitsubishi Tanabe Pharma Corporation, Sanofi, and BrainStorm Cell Therapeutics. Biogen is notable for QALSODY, the first FDA-approved therapy targeting the genetic cause of SOD1-ALS. Mitsubishi Tanabe Pharma markets edaravone (RADICAVA), an FDA-approved drug that slows ALS progression. Sanofi, known for Rilutek (riluzole), has played a significant role as riluzole remains a first-line FDA-approved therapy for ALS. BrainStorm Cell Therapeutics focuses on innovative stem cell therapies, contributing to the evolving ALS treatment landscape.
These companies collectively command the largest market share in ALS therapeutics in the U.S., driving developments in medications, gene therapies, and stem cell treatments. The U.S. market leads due to strong commercial presence, favorable reimbursement policies, and extensive research funding. Alongside drug development, firms engage in clinical trials to improve management of ALS symptoms and slow progression, aiming to meet high unmet medical needs in this progressive neurodegenerative disease.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Amyotrophic Lateral Sclerosis (ALS) Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in ALS treatment in the United States are Biogen, Mitsubishi Tanabe Pharma Corporation, Sanofi, and BrainStorm Cell Therapeutics. Biogen is notable for QALSODY, the first FDA-approved therapy targeting the genetic cause of SOD1-ALS. Mitsubishi Tanabe Pharma markets edaravone (RADICAVA), an FDA-approved drug that slows ALS progression. Sanofi, known for Rilutek (riluzole), has played a significant role as riluzole remains a first-line FDA-approved therapy for ALS. BrainStorm Cell Therapeutics focuses on innovative stem cell therapies, contributing to the evolving ALS treatment landscape.
These companies collectively command the largest market share in ALS therapeutics in the U.S., driving developments in medications, gene therapies, and stem cell treatments. The U.S. market leads due to strong commercial presence, favorable reimbursement policies, and extensive research funding. Alongside drug development, firms engage in clinical trials to improve management of ALS symptoms and slow progression, aiming to meet high unmet medical needs in this progressive neurodegenerative disease.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
